ProMIS Capex To Operating Cash Flow vs Ev To Sales Analysis

PMN Stock

USD 0.92 0.11 10.68%

ProMIS Neurosciences financial indicator trend analysis is much more than just breaking down ProMIS Neurosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ProMIS Neurosciences is a good investment. Please check the relationship between ProMIS Neurosciences Capex To Operating Cash Flow and its Ev To Sales accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.

Capex To Operating Cash Flow vs Ev To Sales

Capex To Operating Cash Flow vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ProMIS Neurosciences Capex To Operating Cash Flow account and Ev To Sales. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between ProMIS Neurosciences' Capex To Operating Cash Flow and Ev To Sales is -0.18. Overlapping area represents the amount of variation of Capex To Operating Cash Flow that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of ProMIS Neurosciences, assuming nothing else is changed. The correlation between historical values of ProMIS Neurosciences' Capex To Operating Cash Flow and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Operating Cash Flow of ProMIS Neurosciences are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Capex To Operating Cash Flow i.e., ProMIS Neurosciences' Capex To Operating Cash Flow and Ev To Sales go up and down completely randomly.

Correlation Coefficient

-0.18

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Capex To Operating Cash Flow

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from ProMIS Neurosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ProMIS Neurosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.At this time, ProMIS Neurosciences' Selling General Administrative is very stable compared to the past year. As of the 27th of November 2024, Issuance Of Capital Stock is likely to grow to about 24.4 M, while Sales General And Administrative To Revenue is likely to drop 348.08.

	2021	2023	2024 (projected)
Cost Of Revenue	5.9M	10.4M	11.3M
Interest Income	4.7K	5.4K	5.7K

Cost Of Revenue Interest Income

ProMIS Neurosciences fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Other Current Liab	Non Currrent Assets Other	Common Stock	Good Will	Current Deferred Revenue	Short Long Term Debt Total	Short Term Debt
Total Assets		0.7	0.81	-0.21	-0.98	-0.74	0.69	0.99	-0.7	1.0	0.4	0.8	-0.03	0.62	0.84	0.9	0.98	1.0	-0.66	0.56	0.04	0.51	0.17	-0.64	0.62	0.69
Total Current Liabilities	0.7		0.34	-0.22	-0.78	-0.89	0.95	0.69	-0.62	0.68	0.48	0.94	-0.17	-0.06	0.93	0.92	0.76	0.7	-0.55	0.81	0.18	0.53	0.13	-0.84	0.62	0.88
Total Stockholder Equity	0.81	0.34		-0.07	-0.73	-0.28	0.47	0.76	-0.54	0.82	0.31	0.47	0.32	0.55	0.51	0.52	0.68	0.81	-0.51	0.08	-0.31	0.08	0.17	-0.52	0.34	0.52
Property Plant And Equipment Net	-0.21	-0.22	-0.07		0.29	0.29	-0.24	-0.28	0.64	-0.2	-0.09	-0.24	0.54	-0.13	-0.39	-0.21	-0.24	-0.21	-0.23	-0.03	-0.53	-0.26	0.4	0.19	-0.08	-0.21
Net Debt	-0.98	-0.78	-0.73	0.29		0.83	-0.77	-0.99	0.71	-0.98	-0.39	-0.88	0.18	-0.54	-0.91	-0.93	-0.99	-0.98	0.61	-0.6	-0.19	-0.62	-0.11	0.69	-0.67	-0.78
Retained Earnings	-0.74	-0.89	-0.28	0.29	0.83		-0.79	-0.78	0.62	-0.72	-0.33	-0.96	0.45	-0.21	-0.92	-0.91	-0.84	-0.74	0.58	-0.84	-0.46	-0.84	0.03	0.66	-0.82	-0.79
Accounts Payable	0.69	0.95	0.47	-0.24	-0.77	-0.79		0.69	-0.58	0.68	0.48	0.9	-0.13	-0.1	0.89	0.85	0.72	0.7	-0.43	0.6	0.14	0.39	0.13	-0.93	0.51	0.93
Cash	0.99	0.69	0.76	-0.28	-0.99	-0.78	0.69		-0.68	0.99	0.36	0.82	-0.18	0.64	0.86	0.89	0.99	0.99	-0.59	0.54	0.18	0.59	0.11	-0.64	0.64	0.7
Non Current Assets Total	-0.7	-0.62	-0.54	0.64	0.71	0.62	-0.58	-0.68		-0.69	-0.37	-0.67	0.03	-0.28	-0.77	-0.67	-0.67	-0.7	0.57	-0.55	-0.03	-0.4	0.18	0.49	-0.53	-0.57
Cash And Short Term Investments	1.0	0.68	0.82	-0.2	-0.98	-0.72	0.68	0.99	-0.69		0.39	0.79	-0.02	0.64	0.83	0.88	0.97	1.0	-0.66	0.53	0.03	0.5	0.17	-0.63	0.6	0.68
Net Receivables	0.4	0.48	0.31	-0.09	-0.39	-0.33	0.48	0.36	-0.37	0.39		0.42	0.14	-0.01	0.4	0.45	0.38	0.4	-0.27	0.36	-0.14	0.01	0.17	-0.51	0.22	0.34
Common Stock Shares Outstanding	0.8	0.94	0.47	-0.24	-0.88	-0.96	0.9	0.82	-0.67	0.79	0.42		-0.28	0.15	0.96	0.93	0.86	0.8	-0.63	0.78	0.28	0.69	0.02	-0.82	0.79	0.9
Short Term Investments	-0.03	-0.17	0.32	0.54	0.18	0.45	-0.13	-0.18	0.03	-0.02	0.14	-0.28		-0.1	-0.26	-0.17	-0.19	-0.03	-0.35	-0.11	-1.0	-0.64	0.39	0.1	-0.28	-0.16
Non Current Liabilities Total	0.62	-0.06	0.55	-0.13	-0.54	-0.21	-0.1	0.64	-0.28	0.64	-0.01	0.15	-0.1		0.21	0.32	0.59	0.62	-0.29	0.06	0.11	0.36	0.06	0.09	0.26	-0.03
Other Current Assets	0.84	0.93	0.51	-0.39	-0.91	-0.92	0.89	0.86	-0.77	0.83	0.4	0.96	-0.26	0.21		0.95	0.89	0.85	-0.59	0.77	0.26	0.64	0.08	-0.79	0.74	0.85
Other Stockholder Equity	0.9	0.92	0.52	-0.21	-0.93	-0.91	0.85	0.89	-0.67	0.88	0.45	0.93	-0.17	0.32	0.95		0.94	0.9	-0.64	0.79	0.18	0.61	0.16	-0.74	0.66	0.79
Total Liab	0.98	0.76	0.68	-0.24	-0.99	-0.84	0.72	0.99	-0.67	0.97	0.38	0.86	-0.19	0.59	0.89	0.94		0.98	-0.63	0.64	0.2	0.63	0.15	-0.65	0.66	0.71
Total Current Assets	1.0	0.7	0.81	-0.21	-0.98	-0.74	0.7	0.99	-0.7	1.0	0.4	0.8	-0.03	0.62	0.85	0.9	0.98		-0.66	0.56	0.04	0.51	0.17	-0.64	0.62	0.69
Intangible Assets	-0.66	-0.55	-0.51	-0.23	0.61	0.58	-0.43	-0.59	0.57	-0.66	-0.27	-0.63	-0.35	-0.29	-0.59	-0.64	-0.63	-0.66		-0.74	0.35	-0.46	-0.11	0.31	-0.69	-0.51
Other Current Liab	0.56	0.81	0.08	-0.03	-0.6	-0.84	0.6	0.54	-0.55	0.53	0.36	0.78	-0.11	0.06	0.77	0.79	0.64	0.56	-0.74		0.11	0.65	0.14	-0.45	0.76	0.55
Non Currrent Assets Other	0.04	0.18	-0.31	-0.53	-0.19	-0.46	0.14	0.18	-0.03	0.03	-0.14	0.28	-1.0	0.11	0.26	0.18	0.2	0.04	0.35	0.11		0.64	-0.38	-0.1	0.29	0.17
Common Stock	0.51	0.53	0.08	-0.26	-0.62	-0.84	0.39	0.59	-0.4	0.5	0.01	0.69	-0.64	0.36	0.64	0.61	0.63	0.51	-0.46	0.65	0.64		-0.2	-0.21	0.79	0.54
Good Will	0.17	0.13	0.17	0.4	-0.11	0.03	0.13	0.11	0.18	0.17	0.17	0.02	0.39	0.06	0.08	0.16	0.15	0.17	-0.11	0.14	-0.38	-0.2		-0.12	0.02	0.08
Current Deferred Revenue	-0.64	-0.84	-0.52	0.19	0.69	0.66	-0.93	-0.64	0.49	-0.63	-0.51	-0.82	0.1	0.09	-0.79	-0.74	-0.65	-0.64	0.31	-0.45	-0.1	-0.21	-0.12		-0.45	-0.81
Short Long Term Debt Total	0.62	0.62	0.34	-0.08	-0.67	-0.82	0.51	0.64	-0.53	0.6	0.22	0.79	-0.28	0.26	0.74	0.66	0.66	0.62	-0.69	0.76	0.29	0.79	0.02	-0.45		0.6
Short Term Debt	0.69	0.88	0.52	-0.21	-0.78	-0.79	0.93	0.7	-0.57	0.68	0.34	0.9	-0.16	-0.03	0.85	0.79	0.71	0.69	-0.51	0.55	0.17	0.54	0.08	-0.81	0.6

Click cells to compare fundamentals

ProMIS Neurosciences Account Relationship Matchups

ProMIS Neurosciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	2.1M	1.4M	22.4M	9.4M	18.0M	18.9M
Total Current Liabilities	1.7M	2.4M	1.2M	8.7M	12.4M	13.0M
Total Stockholder Equity	398.1K	(1.0M)	7.2M	(1.8M)	5.0M	5.2M
Property Plant And Equipment Net	0.0	99.6K	5.9K	434.62	391.16	371.6
Net Debt	(1.7M)	(1.0M)	(16.5M)	(8.0M)	(16.7M)	(15.9M)
Retained Earnings	(65.6M)	(71.2M)	(78.6M)	(108.7M)	(123.8M)	(117.6M)
Accounts Payable	465.0K	437.5K	409.0K	3.0M	10.4M	10.9M
Cash	1.7M	1.0M	21.4M	8.0M	16.7M	17.5M
Non Current Assets Total	48.3K	144.2K	40.8K	28.6K	25.8K	24.5K
Cash And Short Term Investments	1.7M	1.1M	21.5M	8.0M	16.8M	17.6M
Net Receivables	56.8K	31.0K	48.7K	71.6K	64.5K	110.2K
Common Stock Shares Outstanding	4.3M	4.8M	5.8M	7.5M	12.3M	12.9M
Short Term Investments	41.8K	76.7K	50.7K	59.5K	61.6K	58.6K
Liabilities And Stockholders Equity	2.1M	1.4M	22.4M	6.9M	17.4M	18.2M
Non Current Liabilities Total	1.1M	437.5K	14.1M	1.9M	683.9K	649.7K
Inventory	(56.8K)	(31.0K)	(48.7K)	(71.6K)	(64.5K)	(61.2K)
Other Current Assets	321.8K	135.0K	688.6K	925.1K	1.3M	1.4M
Other Stockholder Equity	8.1M	28.9M	85.8M	107.0M	129.3M	135.8M
Total Liab	1.7M	2.4M	15.3M	8.7M	13.1M	13.7M
Total Current Assets	2.0M	1.2M	22.4M	9.3M	18.0M	18.9M
Accumulated Other Comprehensive Income	8.9M	9.1M	(237.6K)	(264.5K)	(491.8K)	(467.2K)
Intangible Assets	48.3K	41.6K	34.9K	28.2K	25.4K	43.6K
Other Current Liab	1.2M	1.4M	765.9K	3.4M	2.0M	2.1M
Common Stock	45.2M	49.0M	52.7M	56.5M	65.0M	38.3M
Good Will	(12.6K)	(14.6K)	(11.3K)	(9.0K)	(8.1K)	(8.5K)
Net Tangible Assets	349.8K	(1.1M)	7.4M	(1.4M)	(1.6M)	(1.5M)
Net Invested Capital	304.8K	(796.7K)	9.7M	(1.3M)	(1.5M)	(1.5M)
Net Working Capital	267.8K	(909.8K)	16.7M	490.4K	564.0K	535.8K

Pair Trading with ProMIS Neurosciences

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProMIS Neurosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProMIS Neurosciences will appreciate offsetting losses from the drop in the long position's value.

Moving together with ProMIS Stock

0.84	FDMT	4D Molecular Therapeutics	Pair Corr
0.62	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.81	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

Moving against ProMIS Stock

0.76	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.74	NAMS	NewAmsterdam Pharma	Pair Corr
0.54	ESLAW	Estrella Immunopharma	Pair Corr
0.52	PHVS	Pharvaris BV	Pair Corr
0.5	PMVP	Pmv Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to ProMIS Neurosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProMIS Neurosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProMIS Neurosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProMIS Neurosciences to buy it.

The correlation of ProMIS Neurosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProMIS Neurosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProMIS Neurosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ProMIS Neurosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether ProMIS Neurosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ProMIS Neurosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Promis Neurosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Promis Neurosciences Stock:

How To Invest In ProMIS

Details

Is ProMIS Stock a good investment?

Details

What is ProMIS Neurosciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProMIS Neurosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in ProMIS Stock, please use our How to Invest in ProMIS Neurosciences guide.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProMIS Neurosciences. If investors know ProMIS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProMIS Neurosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

0.04

Revenue Per Share

0.001

Return On Assets

(4.81)

Return On Equity

(10.99)

The market value of ProMIS Neurosciences is measured differently than its book value, which is the value of ProMIS that is recorded on the company's balance sheet. Investors also form their own opinion of ProMIS Neurosciences' value that differs from its market value or its book value, called intrinsic value, which is ProMIS Neurosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProMIS Neurosciences' market value can be influenced by many factors that don't directly affect ProMIS Neurosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ProMIS Neurosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProMIS Neurosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProMIS Neurosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ProMIS Capex To Operating Cash Flow vs Ev To Sales Analysis

Capex To Operating Cash Flow vs Ev To Sales

Capex To Operating Cash Flow vs Ev To Sales Correlation Analysis

Correlation Coefficient

Capex To Operating Cash Flow

Ev To Sales

ProMIS Neurosciences fundamental ratios Correlations

ProMIS Neurosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ProMIS Neurosciences fundamental ratios Accounts

Pair Trading with ProMIS Neurosciences

Moving together with ProMIS Stock

Moving against ProMIS Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash
Total Liab	+ 0.99	Cash

Non Currrent Assets Other	- 1.0	Short Term Investments
Total Liab	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Total Current Assets	- 0.98	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Net Debt	- 0.98	Total Assets